OrbusNeich has issued a press release suggesting that clinical data published in the International Journal of Cardiology suggests its Genous™ Stent is safe and effective in patients who discontinue Dual Antiplatelet Therapy (DAPT) within 15 days of stent placement. Specifically, no differences in rates of stent thrombosis (ST) and other clinical outcomes were observed between patients who discontinued DAPT prior to and after 15 days, according to the results of ARGENTO, a consecutive, prospective study in 384 patients undergoing single or multivessel percutaneous coronary intervention (PCI) with the Genous Stent.
Hong Kong-based vascular disease device company OrbusNeich has appeared on our pages before, most recently here with the news that its Genous stent, which is coated with endothelial progenitor cells, gives rise to an improved neointima. Quite big news that, and now the technology is getting some more favourable coverage, as it appears from a published clinical study, that it works well enough to obviate the need for extended dual antiplatelet cover for implantees.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products include the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC.
Development stage products include the Combo Dual Therapy Stent™, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.
OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries.
In the study, codenamed ARGENTO, the rate of major adverse cardiac events (MACE) in all patients at follow up (22.8 +/- 13.6 months) was 8.6 percent. The rate of cardiac death was 3.4 percent, and myocardial infarction (MI) similarly occurred in 3.4 percent of patients. In addition, the rate of target vessel revascularisation (TVR) was 4.7 percent. The overall rate of definite or probable stent thrombosis (ST) was 1.3 percent.
Although not statistically significant, the rates of MACE (4.4 percent for discontinued DAPT; 9.9 percent for continued DAPT) and TVR (1.1 percent for discontinued DAPT; 5.8 percent for continued DAPT) were lower in the patient group that received a shorter duration of DAPT.
Definite or probable ST occurred in 1.1 percent of patients who discontinued DAPT prior to or at 15 days and in 1.3 percent of patients who received DAPT beyond 15 days.
Paolo Scacciatella, M.D., of the Department of Cardiovascular and Thoracic Diseases, S. Giovanni Battista University Hospital, Turin, Italy, and a co-author of the publication, said, “The ARGENTO results confirm the safety and efficacy of the Genous Stent when combined with a very short duration of DAPT. These data are similar to those in previous studies that suggest that the Genous Stent may also be an important alternative for high-risk patients and for those undergoing undeferrable non-cardiac surgery.”
“In patients treated with the Genous Stent, DAPT duration does not appear to predict risk for fatal events, such as ST or MI, typically associated with the premature discontinuation of antiplatelet agents following treatment with a stent,” said Federico Piscione, M.D., of the Federico II University in Naples, Italy, and corresponding author of the publication. “In fact, we observe a trend toward improved outcomes for patients who discontinue DAPT within 15 days of stenting. Taken together, these data suggest that the Genous Stent is a safe and effective option for patients with expected or known low compliance to long-term DAPT.”
Availability and status
The Genous Stent has been commercially available in more than 60 countries since 2005. It has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 8,000 patients in clinical studies.
Source: Orbusneich Inc., PR Newswire